ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) Share Price

Company Profile

Business description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Contact
1000 Zhangheng Road
Unit 15, China (Shanghai) Pilot Free Trade Zone
Pudong New Area
Shanghai
CHN
T: +86 2138016387
https://cn.immuneonco.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
202

Recommended

ASX tech share raises funds to facilitate customer AI spend.

Roy Van Keulen | 08 June 2026

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.

Harrison Rolfes | 05 June 2026

ASX healthcare giant expected to see uptick in demand from emerging markets.

Lochlan Halloway, CFA | 05 June 2026

Index	Last price	Change	% Change
All Ordinaries	8,824.80	67.50	0.77%
CAC 40	8,199.29	18.95	-0.23%
DAX 40	24,616.22	142.83	-0.58%
Dow JONES (US)	50,786.01	80.77	-0.16%
FTSE 100	10,373.20	5.15	0.05%
HKSE	24,697.00	39.94	0.16%
NASDAQ	25,929.66	220.23	0.86%
Nikkei 225	65,416.63	1,392.03	2.17%
NZX 50 Index	13,204.08	165.84	1.27%
S&P 500	7,405.73	21.99	0.30%
S&P/ASX 200	8,604.20	70.70	0.83%
SSE Composite Index	4,008.54	49.20	1.24%